EKF Diagnostics Holdings plc
("EKF" or "the Company")
Investor Teach-In
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, has announced that it will be delivering a presentation to investors to provide an overview of the business later today.
A presentation of the business will be given by the Company's CEO to provide more information on the Company's strategy, vision of the market and overview of the product suite. No new material trading or financial information will be disclosed.
To register to attend the investor teach-in, please contact Walbrook PR (details below).
The presentation will shortly be available to view at www.ekfdiagnostics.com
Enquiries:
Walbrook PR Limited |
Tel: 020 7933 8780 or [email protected] |
Lianne Cawthorne (Media Enquiries) |
|
Paul Cornelius (Investor Enquiries) |
|
About EKF Diagnostics Holdings plc
EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010 for a maximum of £5.41m), Argutus Medical Limited (acquired in December 2010 for £2.18m) and Stanbio Laboratory L.P. (acquired in June 2011 for a maximum of US$25.5m).
The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focused on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.
In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.
On the 4 March 2013, EKF announced the establishment of EKF Molecular Diagnostics Ltd to offer innovative products with the potential to change current DNA extraction and detection practices, enabling EKF to address the fast growing companion diagnostics market.
For more information please visit the website: www.ekfdiagnostics.com
